As novel biotherapeutics progress through the clinic and on to the market, toxicities generated due to the expression of the targeted antigens on healthy tissues represent a key concern linked with significant long-term morbidities and mortality.
​
Through direct experience in the NHS and with a leading Antibody Drug Conjugate ("ADC") sector specialist, the BiVictriX team has developed the Bi-Cygni technology. Bi-Cygni therapeutics target a novel cancer-restricted cell-surface fingerprint, which is absent from healthy cells. Enabling the development of anti-cancer drugs with a marked increase in tumour selectivity, together with improved potency.
​
​
